Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.07), $0.19 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $19.53 million versus the consensus estimate of $18.37 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.